logo
logo

Exo Therapeutics Launches with $25 Million Series A Financing to Unlock Intractable Drug Targets with Exosites

Dec 16, 2020•almost 5 years ago

Amount Raised

$25 Million

Round Type

series a

Cambridge

Description

Exo Therapeutics, Inc., a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets, today announced the completion of a $25 million Series A financing. Investors in the round included Newpath Partners, Novartis Venture Fund, CRV and 6 Dimensions Capital.

Company Information

Company

Exo Therapeutics

Location

Cambridge, Maryland, United States

About

Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company's team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases. For more information, visit www.exo-therapeutics.com.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech